Art

J-GLOBAL ID：201902246731639009   Reference number：19A2911954

Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells

ヒト白血病K562細胞におけるウォッシュアウト後のBCR-ABLチロシンキナーゼ阻害剤(TKI)の連続的細胞静止効果

Author (5)： Aoyama Tsuyoshi (Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) ,  Shibayama Yoshihiko (Department of Drug Fomulation, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido) ,  Furukawa Tatsuhiko (Department of Molecular Oncology, Graduate School Medical and Dental Sciences, Kagoshima University) ,  Sugawara Mitsuru (Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) ,  Takekuma Yoh (Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
Material： Biological and Pharmaceutical Bulletin (Web)
Volume： 42  Issue： 11  Page： 1805-1813(J-STAGE)  Publication year： 2019 
JST Material Number： U1402A  ISSN： 1347-5215  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： K562 cell ,...
Semi thesaurus term： cell physiology ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A2911954&from=J-GLOBAL&jstjournalNo=U1402A") }}

Author keywords (10)： tyrosine kinase inhibitor ,  cytostatic effect ,  multidrug resistance protein-1 ,  chronic myeloid leukemia ,  P-glycoprotein ,  tyrosine kinase inhibitor ,  cytostatic effect ,  multidrug resistance protein-1 ,  chronic myeloid leukemia ,  P-glycoprotein

JST classification (1)： Basic research of antitumor(=antineoplastic)drugs  (GW16010A)

Substance index (3)： Imatinib ,  Dasatinib ,  Nilotinib

Reference (34)：

• 1) Nowell PC. The minute chromosome (Ph1) in chronic granulocytic leukemia. Ann. Hematol., 8, 65-66 (1962).
• 2) Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290-293 (1973).
• 3) Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer, 5, 172-183 (2005).
• 4) Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev., 18, 459-471 (2007).
• 5) Larson RA, Druker BJ, Guilhot F, O’Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, 111, 4022-4028 (2008).

Terms in the title (7)： ヒト ,  白血病K562細胞 ,  ウォッシュアウト ,  BCR-ABL ,  チロシンキナーゼ阻害剤 ,  細胞 ,  静止